Document is current
Any future updates will be listed below
-
Authors
Hansen, Niels https://orcid.org/0000-0001-5785-9594
Knopp, Clara Maria
Esselmann, Hermann https://orcid.org/0000-0001-5484-9710
Celano, Christopher M. https://orcid.org/0000-0003-0547-2851
Derad, Carlotta https://orcid.org/0000-0001-9542-4647
Asendorf, Thomas
Chebbok, Mohammed
Heinemann, Stephanie https://orcid.org/0000-0002-3937-5956
Malik, Ihtzaz
Morgado, Barbara
Becker, Matilda-Marie
Günther, Irina
Krasiuk, Iryna
Packroß, Katharina
Rediske, Alina Isabel
Süttmann, Nicholas Paul
Titsch, Tobias
Kutschka, Ingo
Baraki, Hassina
Wiltfang, Jens https://orcid.org/0000-0003-1492-5330
von Arnim, Christine A. F. https://orcid.org/0000-0002-8614-2223
Sadlonova, Monika https://orcid.org/0000-0003-3629-252X
,
Wiesent, Adriana
Jahn-Brodmann, Anke
Thiel, Anne-Catherine
Gaß, Annika
Morgado, Barbara
Schott, Björn Hendrik
Albert, Britta
Eberhard, Charlotte
von Arnim, Christine A. F.
Knopp, Clara Maria
Bauer, Frederike E.
Schmitz, Jessica
Ehrentraut, Julia
Hohberg, Maike
Santander, Manuel J.
Alexy, Maria
Dornieden, Maria
Knierim, Maria
Richter, Marianne
Hotheit, Melania
Moser, Michael
Schröder, Miriam F.
Itting, Paul T.
Arentz, Rebecca
Kastenbauer, Sandra
Martinez, Santander
Johannes, Manuel
Doerfler, Sophie
Chiwakata, Tendai
Kruck, Theresa Maria
- License Information
-
More Information
Article History
Received: 26 March 2024
Revised: 19 November 2025
Accepted: 2 December 2025
First Online: 22 December 2025
Change Date: 27 January 2026
Change Type: Update
Change Details: Unfortunately, an error occurred during the processing of the queries. Reference 53 was mistakenly removed from the reference list, although this was not requested in our responses or correction files. Only citation (53) in the main text was to be deleted. To correct this, the supplementary material has been revised. Reference 53 has been reinstated as a written source for Supplementary Table 7.
Competing interests
: CMC has received funding from the National Heart, Lung, and Blood Institute (grant R01HL155301) and stipends from Elsevier for editorial work for General Hospital Psychiatry. JW has served at scientific advisory boards for Abbot, Biogen, Boehringer-Ingelheim, Eli Lilly, F. Hoffmann-La Roche, Immunogenetics, MSD SHARP & DOHME, he has also received honorarium for lectures sponsored by Eli Lilly, Pfizer, Janssen, MSD SHARP & DOHME, Amgen, Roche Pharma, Actelion Pharmaceuticals, Guangzhou Glorylen Medical Technology Co. (China), Beijing Yibai Science and Technology Ltd. CAFvA has received honoraria from serving on the scientific advisory board of Biogen, Roche, Lilly and Dr. Willmar Schwabe GmbH &Co. CAFvA has also received funding for travel and speaker honoraria from Biogen, Roche diagnostics AG, Novo Nordisk, MedTrixGmbH, Landesvereinigung für Gesundheit und Akademie für Sozialmedizin Niedersachsen e. V., Medical Tribune Verlagsgesellschaft mbH, Novartis, FomF GmbH, Paracelsus–Kliniken Deutschland, Schön Klinik Bad Aibling and Dr. Willmar Schwabe GmbH &Co. NH has received funding support from the DFG (project number 5302297989) and receives travel support from Eli Lilly and Company. MS, HE, CD, TA, MC, SH, AW, JS, FEB, JE, IG, HB report no competing interests.
: The study protocol was approved by the Ethics Committee of the University of Göttingen Medical Center on February 16, 2021 (#20/11/20). Written informed consent is obtained from each participant before any trial‑related procedures are performed and patients receive a copy of the signed and dated written consent form. All methods were performed in accordance with the relevant guidelines and regulations.
